4523 Stock Overview
Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥5,570.00 |
| 52 Week High | JP¥9,614.00 |
| 52 Week Low | JP¥4,986.00 |
| Beta | -0.066 |
| 11 Month Change | -16.04% |
| 3 Month Change | -18.00% |
| 1 Year Change | -41.41% |
| 33 Year Change | -39.32% |
| 5 Year Change | 3.92% |
| Change since IPO | 242.02% |
Recent News & Updates
Recent updates
Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Aug 08
Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00
Jul 25Is Eisai (TSE:4523) A Risky Investment?
Jul 11Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Jul 11Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark
Jun 10Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly
Apr 11Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Mar 18Eisai's (TSE:4523) Dividend Will Be ¥80.00
Mar 04Shareholder Returns
| 4523 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 1.8% | -4.2% | -8.5% |
| 1Y | -41.4% | 7.7% | 5.2% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 5.2% over the past year.
Price Volatility
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in JP Market | 9.9% |
| 10% least volatile stocks in JP Market | 3.3% |
Stable Share Price: 4523's share price has been volatile over the past 3 months.
Volatility Over Time: 4523's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,067 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| 4523 fundamental statistics | |
|---|---|
| Market cap | JP¥1.58t |
| Earnings (TTM) | JP¥32.65b |
| Revenue (TTM) | JP¥733.85b |
48.5x
P/E Ratio2.2x
P/S RatioIs 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 income statement (TTM) | |
|---|---|
| Revenue | JP¥733.85b |
| Cost of Revenue | JP¥151.17b |
| Gross Profit | JP¥582.68b |
| Other Expenses | JP¥550.03b |
| Earnings | JP¥32.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
| Earnings per share (EPS) | 114.81 |
| Gross Margin | 79.40% |
| Net Profit Margin | 4.45% |
| Debt/Equity Ratio | 19.8% |
How did 4523 perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield141%
Payout RatioDoes 4523 pay a reliable dividends?
See 4523 dividend history and benchmarks| Eisai dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Nov 18 2024 |
| Days until Ex dividend | 48 days |
| Days until Dividend pay date | 100 days |
Does 4523 pay a reliable dividends?
See 4523 dividend history and benchmarks